Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Transplantation and Cellular Therapy|December 27, 2023
Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World ExperienceDanai Dima, James A Davis, Nausheen Ahmed, et al.
JCO Oncology Practice|October 2, 2025
Impact of Publicly Reported Outcomes on Patient Selection for Hematopoietic Cell TransplantationChristopher Strouse, Mark Juckett, Brent R Logan, et al.
Cancers|March 14, 2026
A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment-USMIRC GroupMaha Hameed, Alma Habib, Abdullah Mohammad Khan, et al.
Cancers|March 28, 2024
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell TransplantationWancheng Guo, Christopher Strouse, David Mery, et al.
Expert Review of Hematology|May 27, 2026
From episodic assessment to comprehensive assessment: integrating real-world monitoring in relapsed/refractory multiple myelomaCarmel Awadallah, Shebli Atrash, Barry Paul, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Evaluation of Real-World Studies on Management of Relapsed Multiple Myeloma After BCMA-Directed Therapy Failure from U.S. Academic Centers and USMIRCNagham Youssef, Maha Hameed, Shebli Atrash, et al.
Blood Advances|November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO ConsortiumJonathan R Day, Melissa C Larson, Urshila Durani, et al.
Haematologica|November 30, 2023
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphomaMatthew J Maurer, Carla Casulo, Melissa C Larson, et al.
The Lancet. Haematology|March 31, 2022
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort studyCarla Casulo, Melissa C Larson, Julianne J Lunde, et al.
Cancer|April 6, 2023
Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myelomaNaresh Bumma, Binod Dhakal, Raphael Fraser, et al.
Pageof 4